2026 Frost & Sullivan Summit – Full Agenda of the Life Science New Investment Forum Revealed

The Frost & Sullivan Growth, Innovation and Leadership Best Practices Award (referred to as 'GIL Award') aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of this award have been widely recognized by the investment and financial communities as well as within the industry. To date, over 5,000 excellent companies have been recognized globally.

2026 marks the 65th anniversary of Frost & Sullivan’s global establishment,Frost & Sullivan Chinawill continue to track and study numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries within China during 2026. It will conduct objective analysis and comprehensive evaluation of the innovation capabilities, business models, founding teams, technical abilities, and future prospects of participating companies, and together with a professional review committee, select several outstanding biotech leadership companies. The winners of the 2026 GIL Award will be announced during this conference at the 65th anniversary celebration of Frost & Sullivan’s global establishment and the 20th anniversary celebration of Frost & Sullivan Summit in China.

At this conference, Frost & Sullivan will release seven blue books covering Hong Kong Stock Exchange 18A, biopharmaceutical exports, gene therapy, brain-computer interfaces, digital intelligent medical imaging,AI healthcareand synthetic biology among other cutting-edge fields. These books focus on the forefront of global technological changes and industrial restructuring, providing deep insights into innovation trends and investment directions in the life and health sector.

English and Chinese Version of the '2026 Hong Kong Stock Exchange 18A Biotech Industry Development Blue Book'

With the acceleration of innovation drug research and development, the continuous improvement of Hong Kong Stock Exchange’s capital market systems, and multiple factors in the transformation and upgrading of China’s biopharmaceutical industry, the 18A rules in the Hong Kong market have gone through pilot exploration and entered a mature development phase of standardization and normalization. The reform of China’s biopharmaceutical capital market has been fully implemented. As a special listing channel for unprofitable biotech companies, the 18A system bridges the gap between innovation research and development and the capital market, helping domestic pharmaceutical companies achieve full-chain breakthroughs from clinical development to industrialization.

Under this background, Frost & Sullivan has compiled this blue book by integrating vast data on the global biotech secondary market, investment and financing in both primary and secondary markets, and IPO issuance transactions. It reviews the ten-year cycle changes in the global biopharmaceutical capital market and the evolution path of 18A policies, and breaks down the 18A sub-industries, popular innovation tracks, and core fundamentals of listed companies. It quantifies valuation and operating data across the entire process from Pre-IPO financing, new share issuance to post-Listing secondary market performance, and also discusses the RWAasset tokenization innovation in Hong Kongdiverse financing models for biopharmaceuticals, and includes authoritative lists such as annual IPO intermediaries, listed companies, and institutional investments. It deeply analyzes the growth prospects, pipeline value, and commercialization potential of each sub-sector, providing quantitative data, industry insights, and decision-making references for biopharmaceutical companies, primary and secondary investors, capital market intermediaries, and industry regulators.

English and Chinese Version of the '2026 China Biopharmaceutical Internationalization Development Blue Book'

For Chinese biopharmaceutical companies, going global is an inevitable choice after completing early capacity accumulation, to actively participate in global industrial division of labor and seek larger market space and higher value realization opportunities. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start innovating. However, as local competition intensifies, payment constraints increase, and similar pipelines become more common, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating China’s innovative strength, considering Chinese companies as important research cooperation partners, asset sources, and industrial chain partners. Based on this, Frost & Sullivan releases the '2026 China Biopharmaceutical Internationalization Development Blue Book' to systematically outline the stage characteristics, driving factors, main paths, and future trends of internationalization development of Chinese biopharmaceutical companies, and discuss the long-term value and development blueprint of the Chinese biopharmaceutical industry in the global market with industry participants, investors, and stakeholders.

English and Chinese Version of the '2026 Global Gene Therapy Industry Development Blue Book'

Driven by continuous technological breakthroughs, improved regulatory frameworks, and capital investment, the gene therapy industry is accelerating from the early technical exploration stage to commercialization. Notably, China’s 15th Five-Year Plan has included bio manufacturing as one of the core directions of strategic emerging industries, and gene therapy has been identified as a key area requiring "key progress." Under the macro-strategy framework of the 15th Five-Year Plan, gene therapy is no longer just a market activity driven by technical exploration and capital, but has become a crucial component of national bi-economic competitiveness, requiring systematic improvements in carrier technology, production process upgrades, clinical conversion efficiency, and regulatory system perfection. However, the industry still faces systemic challenges such as complex production processes, insufficient large-scale production capacity, high shell rate and cost pressure, long-term data verification, and imperfect payment systems. Against this backdrop, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for the development stages, technical systems, and industrial chain structures of the gene therapy industry through this blue book, as well as an in-depth analysis of key process barriers, commercialization paths, and market space, to help industry participants seize opportunities and address challenges.

English and Chinese Version of the '2026 Global Brain-Computer Interface Industry Development White Paper'

Currently, innovative achievements in the field of brain-computer interfaces in China are continuously emerging, and the industry is developing rapidly, becoming an important area where technology innovation and industrial innovation are deeply integrated. By establishing a full-chain ecosystem of "technical innovation—application in scenarios—industrial clustering" and prioritizing review mechanisms, China is accelerating its transition from key technical breakthroughs to global industry leadership, building new advantages for Chinese enterprises in international competition. Against this background, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for industry participants by systematically outlining the development stages, structural features, and evolution paths of the industry, as well as an in-depth analysis of current situations and market space in key application areas, to help them seize opportunities and overcome challenges.

English and Chinese Version of the '2026 Global Digital Intelligent Medical Imaging Ecosystem Industry Development Blue Book'

As artificial intelligence reshapes countless industries at an unprecedented pace, the healthcare sector is undergoing a profound transformation from "experience-driven" to "data intelligence." In this transformation, AI medical imaging is undoubtedly one of the most highly regarded and clinically valuable sectors. However, this integration is leading to deeper qualitative changes: AI is no longer just the "second pair of eyes" of radiologists, but has become a decisive factor in driving the digital intelligent evolution of the medical imaging ecosystem. Starting from the current construction status and challenges of the medical imaging ecosystem, we will analyze how AGI can empower the medical imaging ecosystem, and then look ahead to the future development of the digital intelligent imaging ecosystem. Through this white paper, we hope to enable the public to better understand the development of the medical imaging ecosystem and how AI can truly become a partner and digital twin in doctors' diagnosis and treatment processes.

English and Chinese Version of the '2026 Global AI Healthcare Industry Development Blue Book'

In recent years, with the continuous development of next-generation information technologies such as big data, cloud computing, and the Internet of Things, especially the breakthroughs in generative artificial intelligence and large model technologies, artificial intelligence (AI) has entered a stage of accelerated application worldwide. The healthcare industry, as a data-intensive and highly specialized field, is becoming an important scenario for deep integration of AI. AI is making continuous technological progress in medical imaging, auxiliary diagnosis, disease management, drug research and development, and hospital operation management, promoting the upgrade of the healthcare service system toward intelligence and precision.

Driven by multiple factors including policy support, technological maturity, and capital attention, China’s AI healthcare industry is in a critical period of transitioning from technical validation to large-scale implementation. Industrial chain collaboration is deepening, niche sectors are evolving rapidly, and the industry competition landscape is becoming clearer. How to seize development opportunities during the restructuring of the industrial structure and the upgrading of technical paths has become a core issue for industry participants.

English and Chinese Version of the '2026 Global Synthetic Biology Industry Development White Paper'

Synthetic biology is widely defined by academia and industry as the third life science revolution following the discovery of the DNA double helix structure and the genome technology revolution. The 2026 Government Work Report clearly states the need to foster and grow emerging and future industries, and promote bio manufacturing as a new economic growth point. Synthetic biology and bio manufacturing are no longer just technical issues, but a triple intersection of national security (supply chain autonomy), climate agenda (Dual Carbon/Zero-Carbon Negative Carbon), and economic growth (new quality productivity). Based on long-term insights into global cutting-edge technology and bio-manufacturing industries, Frost & Sullivan launches the '2026 Global Synthetic Biology Industry Development Blue Book', using a comprehensive industrial chain map, country/region comparisons, and a triple lens of regulation-technology-business to deeply understand industry development trends, providing a global perspective for industry professionals.

Life Science New Investment Forum

Event Consultation | Sponsorship Cooperation | Attendance Consultation

📞 Conference Consultation Hotline:

021-3209-6800 ext. 8672

📧 Conference Consultation Email:

gil@frostchina.com